Oticon Medical Launches SmartCharger for the Ponto 5 Family
Oticon Medical today announces the launch of SmartCharger for the Ponto 5 family, introducing its first rechargeable solution for percutaneous sound processors and marking a new step in convenience and portability for bone anchored hearing system users.
Oticon Medical Receives Hearing Technology Innovator Award for Sentio™ System
Oticon Medical is proud to announce that it has been recognized for its Sentio System in the fifth annual Hearing Technology Innovator Awards™ in the category of Auditory Implants: Bone Conduction.
Oticon Medical’s Sentio™ System Receives Regulatory Clearance in the US
Oticon Medical announced today the U.S. Food and Drug Administration (FDA) clearance of its first active transcutaneous bone conduction hearing system, the Sentio System. Sentio System delivers the proven benefits of the Ponto™ System – and more – in a transcutaneous option.
Oticon Medical Announces FDA Premarket Approval for Neuro Cochlear Implant System to Treat Severe to Profound Sensorineural Hearing Loss
Oticon Medical today announced that the US Food and Drug Administration (FDA) has granted premarket approval (PMA) to the company’s Neuro System to treat individuals 18 years or older, with bilateral severe-to-profound sensorineural hearing loss, who obtain limited benefit from appropriately fitted hearing aid(s). With the expansion of its cochlear implant solutions to the US market, Oticon Medical is well positioned to become the world’s leading hearing expert within implantable hearing solutions. People with severe to profound hearing loss in 51 countries already benefit from the Neuro System. The innovative cochlear implant system delivers premium sound quality, award-winning aesthetic design and is designed for outstanding reliability1. The Neuro System is expected to be made available to US hospitals and clinics in 2021.
